Atriva Therapeutics Overview
- Year Founded
-
2015
- Status
-
Out of Business
- Employees
-
7
- Latest Deal Type
-
Liquidation
Atriva Therapeutics General Information
Description
Atriva Therapeutics Inc is a biopharmaceutical company developing host-cell-targeting antiviral and immunomodulatory therapies. It aims to develop novel, highly efficacious and safe therapies for the treatment of severe diseases caused by RNA viruses with a high unmet medical need and huge cost burden to healthcare systems around the world such as influenza, respiratory syncytial virus infections, dengue fever and hantavirus infections. Its lead product zapnometinib is a novel, host-cell-targeting, orally available small molecule drug inhibiting viral replication and rebalancing the body's immune response. The company will primarily focus resources on the development of zapnometinib for the treatment of patients hospitalized with severe influenza infections.
Contact Information
Website
www.atriva-therapeutics.comCorporate Office
- Am Klopferspitz 19
- 82152 Planegg/Martinsried
- Germany
Corporate Office
- Am Klopferspitz 19
- 82152 Planegg/Martinsried
- Germany
Atriva Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Bankruptcy: Liquidation | 24-Apr-2025 | Completed | Bankruptcy: Liquidation | |||
| 9. PIPE | 18-Sep-2023 | Cancelled | Clinical Trials - Phase 2 | |||
| 8. Reverse Merger | 07-Jan-2024 | Cancelled | Clinical Trials - Phase 2 | |||
| 7. Grant | 21-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
| 6. Debt - General | 16-Oct-2020 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC | 11-Aug-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 17-Jul-2019 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 01-Jan-2019 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 21-Sep-2017 | $3.58M | $3.58M | Completed | Pre-Clinical Trials | |
| 1. Grant | 07-Mar-2016 | $1.11K | Completed | Startup |
Atriva Therapeutics Comparisons
Industry
Financing
Details
Atriva Therapeutics Competitors (98)
One of Atriva Therapeutics’s 98 competitors is CytoAgents, a Venture Capital-Backed company based in Pittsburgh, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytoAgents | Venture Capital-Backed | Pittsburgh, PA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| Attune Pharmaceuticals | Venture Capital-Backed | New York, NY | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA |
Atriva Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Atriva Therapeutics Patents
Atriva Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024042050-A1 | Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs | Inactive | 22-Aug-2022 | ||
| EP-4186500-A1 | Mek inhibitors for the prevention and treatment of long covid syndrome | Inactive | 24-Nov-2021 | ||
| EP-4436563-A1 | Mek inhibitors for the prevention and treatment of long covid syndrome | Inactive | 24-Nov-2021 | ||
| WO-2023094556-A1 | Mek inhibitors for the prevention and treatment of long covid syndrome | Inactive | 24-Nov-2021 | ||
| EP-3912623-A1 | Mek-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm | Active | 20-May-2020 | A61K31/4184 |
Atriva Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Atriva Therapeutics FAQs
-
When was Atriva Therapeutics founded?
Atriva Therapeutics was founded in 2015.
-
Where is Atriva Therapeutics headquartered?
Atriva Therapeutics is headquartered in Planegg/Martinsried, Germany.
-
What is the size of Atriva Therapeutics?
Atriva Therapeutics has 7 total employees.
-
What industry is Atriva Therapeutics in?
Atriva Therapeutics’s primary industry is Drug Discovery.
-
Is Atriva Therapeutics a private or public company?
Atriva Therapeutics is a Private company.
-
What is Atriva Therapeutics’s current revenue?
The current revenue for Atriva Therapeutics is .
-
How much funding has Atriva Therapeutics raised over time?
Atriva Therapeutics has raised $45.2M.
-
Who are Atriva Therapeutics’s competitors?
CytoAgents, Inovio Pharmaceuticals, Enterprise Therapeutics, Attune Pharmaceuticals, and Vertex Pharmaceuticals are some of the 98 competitors of Atriva Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
